All Rights Reserved. Forward ® 2019
EBD Group Inc., 3150 Pio Pico Drive, Suite 201, Carlsbad, CA, 92008
When: Monday, January 13 at 4:00 pm
Where: Parc 55 – A Hilton Hotel, 4th Floor, Cyril Magnin Ballroom
What: Free access to the session and reception
FREE Monday Session
January 13–15, 2020
Parc 55 San Francisco – A Hilton Hotel,
San Francisco, CA
Artificial Intelligence is significantly influencing global healthcare including drug development. This discussion will highlight how AI, and specifically, machine learning, is being used to: identify novel therapeutics; find, characterize and intervene on behalf of patients; integrate Social Determinants of Health (SDOH) and other data to provide new insights into patient care; and ultimately enable companies to work more efficiently and effectively. The panel will also explore trends and implications in partnering, business models and capital formation that impact the innovation and adoption of AI in healthcare.
Zavain Dar
Partner
Lux Capital
Ron Alfa
Senior VP, Translational Discovery and Chief Evangelist
Recursion Pharmaceuticals
WITH SUPPORT FROM :
Rafael Rosengarten
CEO and Co-Founder
Genialis, Inc.
Chief Data and Analytics Officer
HVH Precision Analytics
Oodaye Shukla
Anastasia Christianson
VP, R&D Operations and Oncology IT
Janssen Pharmaceutical Companies of Johnson & Johnson
US Pharma and Biotech Correspondent
Financial Times
Hannah Kuchler